Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;3(1):7.
doi: 10.3978/j.issn.2305-5839.2014.10.06.

Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?

Ignacio Veliz  1 , Yong Loo  1 , Omar Castillo  1 , Niki Karachaliou  1 , Olga Nigro  1 , Rafael Rosell  1
Affiliations
Review

Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?

Ignacio Veliz et al. Ann Transl Med. 2015 Jan.

Abstract

Malignant gliomas, such as glioblastoma multiforme (GBM), present some of the greatest challenges in the management of cancer patients worldwide. Even with aggressive surgical resections and recent advances in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal and quality of life is poor. Although new molecular pathways crucial to the biology and invasive ability of GBM are coming to light, translation of basic science achievements into clinical practice is slow. Optimal management requires a multidisciplinary approach and knowledge of potential complications arising from both disease and treatment. To help illustrate "where we are going" with GBM, we here include a detailed depiction of the molecular alterations underlying this fatal disease, as well as intensive research over the past two decades that has led to considerable advances in the understanding of basic GBM biology, pathogenesis and therapeutic approaches.

Keywords: Glioblastoma; targeted therapies; temozolomide (TMZ).

PubMed Disclaimer

Figures

Figure 1
Figure 1
The EGFR pathway in glioblastoma. EGFR, epidermal growth factor receptor.
Figure 2
Figure 2
The NFκB and other signaling pathways in glioblastoma.
See this image and copyright information in PMC

References

    1. Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006;2:494-503; quiz 491 p following 516. - PubMed
    1. Rosell R, de Las Penas R, Balana C, et al. Translational research in glioblastoma multiforme: molecular criteria for patient selection. Future Oncol 2008;4:219-28. - PubMed
    1. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310:1842-50. - PubMed
    1. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15:e395-403. - PubMed
    1. Scherer HJ. A Critical Review: The Pathology of Cerebral Gliomas. J Neurol Psychiatry 1940;3:147-77. - PMC - PubMed